CompletedPhase 3NCT02384122
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
Studying Myelodysplastic neoplasm with low blasts
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Radboud University Medical Center
- Principal Investigator
- Joost Drenth, MD. PhDRadboud University Medical Center
- Intervention
- Octreotide(drug)
- Enrollment
- 62 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2023
Study locations (12)
- Gelre Hospital, Apeldoorn, Gelderland, Netherlands
- Radboud University Medical Center (Radboudumc), Nijmegen, Gelderland, Netherlands
- Jeroen Bosch Hospital, 's-Hertogenbosch, North Brabant, Netherlands
- Catharina Hospital, Eindhoven, North Brabant, Netherlands
- Elisabeth-TweeSteden Hospital, Tilburg, North Brabant, Netherlands
- Reinier de Graaf Gasthuis, Delft, South Holland, Netherlands
- St. Antonius Hospital, Nieuwegein, Utrecht, Netherlands
- Rijnstate Hospital, Arnhem, Netherlands
- University Medical Center Groningen (UMCG), Groningen, Netherlands
- Tjongerschans Hospital, Heerenveen, Netherlands
- Maasstad Hospital, Rotterdam, Netherlands
- Bernhoven Hospital, Uden, Netherlands
Collaborators
Jeroen Bosch Ziekenhuis · Elisabeth-TweeSteden Ziekenhuis · Catharina Ziekenhuis Eindhoven · Bernhoven Hospital · Tjongerschans hospital · Gelre Hospitals · Maasstad Hospital · Reinier de Graaf Groep · University Medical Center Groningen · Rijnstate Hospital · St. Antonius Hospital
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02384122 on ClinicalTrials.govOther trials for Myelodysplastic neoplasm with low blasts
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07328191Quality of Life-Guided Transfusion in Refractory MDS or AMLCentre Hospitalier Universitaire de Nice
- RECRUITINGNCT07019155Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition VariantsNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06918834Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome PatientsInstitute of Hematology & Blood Diseases Hospital, China
- ACTIVE NOT RECRUITINGNCT06144515Collection of Samples of Bone Marrow Aspiration From Patients With Myelodysplastic SyndromeMinovia Therapeutics Ltd.
- RECRUITINGPHASE2NCT05924100Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TDAssociazione Qol-one
- RECRUITINGPHASE1NCT05473910A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem TransplantationTScan Therapeutics, Inc.
- RECRUITINGNCT02269592Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical OutcomeDana-Farber Cancer Institute
See all trials for Myelodysplastic neoplasm with low blasts →